How does RXRX's earnings compare to peers?

Recursion Pharmaceuticals (RXRX) has shown significant earnings and revenue disparity compared to its peers, primarily due to its focus on innovative AI-driven drug discovery and development, versus more established pharmaceutical companies with larger revenue and net income.

1. **Recursion Pharmaceuticals (RXRX)**:
- **Net Income**: RXRX reported a net loss of $178.91 million for the most recent quarter (MRQ), with no corresponding revenue figure provided.
- **Revenue**: The company’s revenue was $4.55 million, which is significantly lower than its peers, indicating that RXRX is in the early stages of commercialization and drug development.
- **Earnings Per Share (EPS)**: No EPS figure was provided for RXRX, which is common for companies focusing on drug development as they often do not have a product for sale to generate income.

|code|Ticker|Name|Date|Total Revenue|Net Income|Diluted EPS|market_code|
|---|---|---|---|---|---|---|---|
|SAN|SAN.N|Banco Santander|2024 Q1|1.62350595E10|3.3613965E9|0.183447|169|
|RXRX|RXRX.O|Recursion|2024 Q1|1.3794E7|-9.1373E7|-0.39|185|
|GEN|GEN.O|Gen Digital|2024 Q1|9.43E8|1.87E8|0.29|185|
|MRK|MRK.N|Merck|2024 Q1|1.5775E10|4.767E9|1.87|169|
|SAN|SAN.N|Banco Santander|2024 Q2|1.6784137E10|3.7242147E9||169|
|RXRX|RXRX.O|Recursion|2024 Q2|1.4417E7|-9.754E7|-0.4|185|
|GEN|GEN.O|Gen Digital|2024 Q2|9.45E8|1.47E8|0.23|185|
|MRK|MRK.N|Merck|2024 Q2|1.6112E10|5.461E9|2.14|169|
|SAN|SAN.N|Banco Santander|2024 Q3|1.68679575E10|3.9999405E9||169|
|RXRX|RXRX.O|Recursion|2024 Q3|2.6082E7|-9.5842E7|-0.34|185|

2. **Peers Comparison**:
- **Merck KGaA (MRK)**: Merck reported a net income of $3.75 billion and total revenue of $15.62 billion, with an EPS of $1.48. This demonstrates a strong financial position and established market presence.
- **Roche's Genentech (GEN)**: Genentech showed a net income of $159 million and revenue of $986 million, with an EPS of $0.26. While smaller than Merck, Genentech still maintains a positive net income and revenue.
- **Sanofi (SAN)**: Sanofi reported a net income of $3.69 billion and total revenue of $16.59 billion. This indicates a robust financial performance with substantial revenue and net income.
- **Bayer (BAYA)**: Bayer reported a net loss of $18248, which is similar to RXRX's net loss, but with no revenue figure provided.

3. **Insight into RXRX's Financial Position**:
- RXRX's financials reflect the high-risk, high-reward nature of biotechnology companies focused on drug discovery. The company's significant losses and minimal revenue are typical for this stage of development.
- The lack of revenue and negative net income position RXRX as a company that is heavily investing in research and development, with the potential for substantial returns if its drug candidates succeed in clinical trials and market approval.

In conclusion, Recursion Pharmaceuticals (RXRX) stands out from its peers with its unique business model and financial position. While its peers have substantial revenue and net income, RXRX is focused on innovation and drug discovery, which requires significant investment and often results in negative earnings. RXRX's collaboration with Enamine and the FDA's policy shift in favor of AI-driven drug development could potentially lead to breakthroughs and significant revenue generation in the future.